Evidence map›Paper›PMID 25517798›Full record

ArticleTissue engineering. Part A2015

Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells.

Brian O Diekman, Pratiksha I Thakore, Shannon K O'Connor, Vincent P Willard, Jonathan M Brunger, Nicolas Christoforou, Kam W Leong, Charles A Gersbach, Farshid Guilak

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. p21Cartilage · 2021
    Article
  6. Article
  7. Long non-coding RNAeLife · 2020
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Brian O Diekman1 Department of Orthopaedic Surgery, Duke University Medical Center , Durham, North Carolina.
Pratiksha I Thakore
Shannon K O'Connor
Vincent P Willard
Jonathan M Brunger
Nicolas Christoforou
Kam W Leong
Charles A Gersbach
Farshid Guilak
Duke Medical Center · USDuke University · USKhalifa University of Science and Technology · AE

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Thermally-Triggered Intra-articular Drug Delivery for OAP01AR050245 · NIAMS · DUKE UNIVERSITY · PI KRAUS, VIRGINIA · 2003 to 2012
$11.5M
VISCOELASTIC PROPERTIES OF NORMAL AND OA CHONDRONSR01AG015768 · NIA · WASHINGTON UNIVERSITY · PI GUILAK, FARSHID · 1998 to 2022
$7.7M
TRAINING PROGRAM IN INFLAMMATORY AND IMMUNOLOGICALT32AI007217 · NIAID · DUKE UNIVERSITY · PI PISETSKY, DAVID STEPHEN · 1985 to 2015
$3.3M
OBESITY, BIOMECHANICS, AND INFLAMMATION IN OSTEOARTHRITISR01AG046927 · NIA · WASHINGTON UNIVERSITY · PI GUILAK, FARSHID · 2013 to 2023
$3.2M
Mechanical and Osmotic Signaling in ChondrocytesR01AR048182 · NIAMS · DUKE UNIVERSITY · PI GUILAK, FARSHID · 2003 to 2013
$3.0M
Engineering Morphogenetic Factors for Enhanced Genetic ReprogrammingDP2OD008586 · OD · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2011
$2.4M
Intrinsic Repair of the Knee MeniscusR01AR048852 · NIAMS · DUKE UNIVERSITY · PI GUILAK, FARSHID · 2007 to 2011
$1.4M
Genome Editing of Stem Cells for Analysis of Osteoarthritis Causal VariantsR21AR065956 · NIAMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A., GUILAK, FARSHID · 2014 to 2015
$382k
Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven ScaffoldsR03AR061042 · NIAMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2013
$224k
NCI NIH HHS P30 CA014236NIAID NIH HHS T32AI007217NIAMS NIH HHS AR061042NIAMS NIH HHS AR065956NIAMS NIH HHS AR48182NIAMS NIH HHS AR48852NIAMS NIH HHS AR50245NIA NIH HHS AG15768NIA NIH HHS AG46927NIGMS NIH HHS T32 GM007171NIH HHS OD008586
6 · The paper itself

Abstract

The limited regenerative capacity of articular cartilage contributes to progressive joint dysfunction associated with cartilage injury or osteoarthritis. Cartilage tissue engineering seeks to provide a biological substitute for repairing damaged or diseased cartilage, but requires a cell source with the capacity for extensive expansion without loss of chondrogenic potential. In this study, we hypothesized that decreased expression of the cell cycle inhibitor p21 would enhance the proliferative and chondrogenic potential of differentiated induced pluripotent stem cells (iPSCs). Murine iPSCs were directed to differentiate toward the chondrogenic lineage with an established protocol and then engineered to express a short hairpin RNA (shRNA) to reduce the expression of p21. Cells expressing the p21 shRNA demonstrated higher proliferative potential during monolayer expansion and increased synthesis of glycosaminoglycans (GAGs) in pellet cultures. Furthermore, these cells could be expanded ∼150-fold over three additional passages without a reduction in the subsequent production of GAGs, while control cells showed reduced potential for GAG synthesis with three additional passages. In pellets from extensively passaged cells, knockdown of p21 attenuated the sharp decrease in cell number that occurred in control cells, and immunohistochemical analysis showed that p21 knockdown limited the production of type I and type X collagen while maintaining synthesis of cartilage-specific type II collagen. These findings suggest that manipulating the cell cycle can augment the monolayer expansion and preserve the chondrogenic capacity of differentiated iPSCs, providing a strategy for enhancing iPSC-based cartilage tissue engineering.

Indexed as

Gene Knockdown TechniquesAnimalsBromodeoxyuridineCartilageCell DifferentiationCell ProliferationCells, CulturedChondrogenesisCollagenCollagen Type ICollagen Type XCyclin-Dependent Kinase Inhibitor p21DNAGene Expression RegulationGlycosaminoglycansImmunohistochemistryBromodeoxyuridineCollagenCollagen Type ICollagen Type XCyclin-Dependent Kinase Inhibitor p21DNAGlycosaminoglycans

Identifiers

PMID25517798
PMCPMC4394871
OpenAlexW2168987028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.